Benjamin Hohl Sells 1,000 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,000 shares of the firm’s stock in a transaction on Monday, March 24th. The stock was sold at an average price of $22.50, for a total value of $22,500.00. Following the completion of the sale, the chief financial officer now directly owns 23,000 shares of the company’s stock, valued at $517,500. This represents a 4.17 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Thursday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $20.41, for a total value of $66,332.50.
• On Wednesday, February 5th, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.52, for a total transaction of $22,520.00.
• On Monday, January 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The shares were sold at an average price of $21.59, for a total transaction of $70,167.50.
• On Friday, January 3rd, Benjamin Hohl sold 1,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.04, for a total transaction of $25,040.00.
• On Monday, December 30th, Benjamin Hohl sold 900 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.51, for a total transaction of $20,259.00.
• On Friday, December 27th, Benjamin Hohl sold 3,350 shares of Enliven Therapeutics stock. The shares were sold at an average price of $22.15, for a total value of $74,202.50.

Enliven Therapeutics Trading Up 4.5 %

Shares of ELVN opened at $21.51 on Friday. Enliven Therapeutics, Inc. has a 12-month low of $15.96 and a 12-month high of $30.03. The company has a market cap of $1.05 billion, a PE ratio of -11.32 and a beta of 1.04. The stock has a 50-day moving average price of $21.29 and a 200-day moving average price of $23.75.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Thursday, March 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.07. The company had revenue of $0.03 million for the quarter. As a group, analysts predict that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have commented on ELVN shares. HC Wainwright raised their target price on Enliven Therapeutics from $37.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, March 21st. BTIG Research initiated coverage on shares of Enliven Therapeutics in a research report on Friday, December 13th. They issued a “buy” rating and a $42.00 price objective for the company. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $38.75.

Institutional Trading of Enliven Therapeutics

Hedge funds have recently made changes to their positions in the stock. Invesco Ltd. increased its stake in Enliven Therapeutics by 3.5% in the fourth quarter. Invesco Ltd. now owns 15,072 shares of the company’s stock valued at $339,000 after acquiring an additional 508 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Enliven Therapeutics by 3.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,036 shares of the company’s stock worth $451,000 after purchasing an additional 718 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Enliven Therapeutics by 230.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company’s stock valued at $36,000 after purchasing an additional 1,114 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of Enliven Therapeutics by 14.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,360 shares of the company’s stock valued at $233,000 after buying an additional 1,275 shares in the last quarter. Finally, MetLife Investment Management LLC lifted its position in Enliven Therapeutics by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 21,746 shares of the company’s stock worth $489,000 after buying an additional 1,285 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.